Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Feb 15;66(2):e0216521.
doi: 10.1128/aac.02165-21. Epub 2021 Dec 20.

In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes

Meredith A Hackel  1 , James A Karlowsky  1   2 , Michele A Canino  3 , Daniel F Sahm  1 , Nicole E Scangarella-Oman  3
Affiliations
Clinical Trial

In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes

Meredith A Hackel et al. Antimicrob Agents Chemother. .

Abstract

Gepotidacin (formerly GSK2140944) is a first-in-class triazaacenaphthylene antibacterial currently in phase III clinical trials. When tested against Gram-negative (n = 333) and Gram-positive (n = 225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates at concentrations of 4 and 2 μg/mL, respectively. Given gepotidacin's in vitro activity against the anaerobic isolates tested, further study is warranted to better understand the utility of gepotidacin in the treatment of infections caused by clinically relevant anaerobic organisms.

Keywords: anaerobes; gepotidacin; inhibitor; topoisomerase; triazaacenaphthylene.

PubMed Disclaimer

Conflict of interest statement

The authors declare a conflict of interest. M.A.C. and N.E.S.-O. are employees and shareholders of GlaxoSmithKline. J.A.K. is a consultant to IHMA. M.A.H. and D.F.S. are employees of IHMA. The IHMA authors do not have personal financial interests in GlaxoSmithKline.

References

    1. Sears CL. 2021. Anaerobic bacterial infections. UpToDate https://www.uptodate.com/contents/anaerobic-bacterial-infections. Accessed 13 May 2021.
    1. Brook I, Wexler HM, Goldstein EJ. 2013. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev 26:526–546. doi: 10.1128/CMR.00086-12. - DOI - PMC - PubMed
    1. Hastey CJ, Boyd H, Schuetz AN, Anderson K, Citron DM, Dzink-Fox J, Hackel M, Hecht DW, Jacobus NV, Jenkins SG, Karlsson M, Knapp CC, Koeth LM, Wexler H, Roe-Carpenter DE. 2016. Changes in the antibiotic susceptibility of anaerobic bacteria from 2007–2009 to 2010–2012 based on the CLSI methodology. Anaerobe 42:27–30. doi: 10.1016/j.anaerobe.2016.07.003. - DOI - PMC - PubMed
    1. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJC, Harrell L, Jenkins S, Newton D, Pierson C, Rihs JD, Yu VL, Venezia R, Finegold SM, Rosenblatt JE, Gorbach SL. 2010. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005–2007). Clin Infect Dis 50(Suppl 1):S26–S33. doi: 10.1086/647940. - DOI - PubMed
    1. Liu CY, Huang YT, Liao CH, Yen LC, Lin HY, Hsueh P-R. 2008. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 52:3161–3168. doi: 10.1128/AAC.00355-08. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources